Expertise in
10
conditions

Dr. Marilyn Raymond

Oncology
Florida Cancer Specialists & Research Institute - GSF
1309 N Flagler Dr, 
West Palm Beach, FL 
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
Florida Cancer Specialists & Research Institute - GSF
1309 N Flagler Dr, 
West Palm Beach, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marilyn Raymond is an Oncologist in West Palm Beach, Florida. Dr. Raymond is highly rated in 10 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and HER2 Negative Breast Cancer. Dr. Raymond is currently accepting new patients.

Her clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Wellington Regional Medical Center
Jupiter Medical Center
Boca Raton Regional Hospital
Good Samaritan Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Florida Cancer Specialists & Research Institute - GSF
1309 N Flagler Dr, West Palm Beach, FL 33401
Other Locations
Florida Cancer Specialists & Research Institute - WLN
1037 S State Road 7 Ste 303, Wellington, FL 33414

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.
EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.
Enrollment Status: Terminated
Publish Date: May 17, 2022
Intervention Type: Other
A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Who Are Candidates for Genomic Testing
A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Who Are Candidates for Genomic Testing
Enrollment Status: Completed
Publish Date: October 13, 2017
View 5 Less Clinical Trials
Similar Doctors
Expertise in
13
conditions
Dr. Luis Raez
Hematology | Oncology
Expertise in
13
conditions
Dr. Luis Raez
Hematology | Oncology

Memorial Cancer Institute

12235 Pines Blvd, 
Pembroke Pines, FL 
 (165.0 miles away)
954-869-5708
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Luis Raez is a Hematologist and an Oncologist in Pembroke Pines, Florida. Dr. Raez is highly rated in 13 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Raez is currently accepting new patients.

Expertise in
87
conditions
Dr. Abraham Schwarzberg
Hematology | Oncology
Expertise in
87
conditions
Dr. Abraham Schwarzberg
Hematology | Oncology

Tampa General Hospital Cancer Center South Florida - Palm Beach

11621 Kew Gardens Ave Ste 101A, 
Palm Beach Gardens, FL 
 (154.1 miles away)
813-302-1571
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Abraham Schwarzberg is a Hematologist and an Oncologist in Palm Beach Gardens, Florida. Dr. Schwarzberg is highly rated in 87 conditions, according to our data. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Schwarzberg is currently accepting new patients.

Expertise in
57
conditions
Dr. Judah Friedman
Oncology
Expertise in
57
conditions
Dr. Judah Friedman
Oncology

Florida Cancer Specialists & Research Institute - GSF

1309 N Flagler Dr, 
West Palm Beach, FL 
 (158.4 miles away)
772-410-3647
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Judah Friedman is an Oncologist in West Palm Beach, Florida. Dr. Friedman is highly rated in 57 conditions, according to our data. His top areas of expertise are Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Friedman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Raymond's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 76 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile